Can Azacitidine Delay Relapse in MRD-Positive AML?
Azacitidine may delay or prevent relapse among patients with MRD-positive acute myeloid leukemia or myelodysplastic syndrome. (Source: CancerNetwork)
Source: CancerNetwork - December 13, 2018 Category: Cancer & Oncology Authors: Bryant Furlow Source Type: news

MRD Effective as Surrogate Endpoint in CLL?
A patient ’s minimal residual disease status may serve as a surrogate marker for outcome in clinical trials of chronic lymphocytic leukemia in patients with comorbidities. (Source: CancerNetwork)
Source: CancerNetwork - December 13, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Testing and Treatment Patterns Rapidly Changing in CLL
Testing patterns associated with the diagnosis and treatment of chronic lymphocytic leukemia have changed rapidly during the last decade. (Source: CancerNetwork)
Source: CancerNetwork - December 11, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Medical News Today: These tiny sensors may detect cancer early
Researchers use nanosensors to detect intracellular interactions that may signal cancer very early on. Their results may help detect lymphocytic leukemia. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 11, 2018 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

Modified citrus pectin can inhibit the growth and metastasis of prostate cancer and kill leukemia cells
(Natural News) Prostate cancer is the second most common cancer among American men, and statistics indicate that there are over two million prostate cancer survivors currently living in the United States. It is most common in men over the age of 65 and is rated as the second most common cause of cancer-related death in... (Source: NaturalNews.com)
Source: NaturalNews.com - December 10, 2018 Category: Consumer Health News Source Type: news

Potential seen for tailoring treatment for acute myeloid leukemia
(University of Washington Health Sciences/UW Medicine) Rapid screening of leukemia cells for drug susceptibility and resistance are bringing scientists closer to patient-tailored treatment for acute myeloid leukemia. Research on the differing drug response patterns of leukemia stem cells and blasts may show why some attempts to treat are not successful and why some patients relapse. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 7, 2018 Category: Cancer & Oncology Source Type: news

LZTR1 is a regulator of RAS ubiquitination and signaling
In genetic screens aimed at understanding drug resistance mechanisms in chronic myeloid leukemia cells, inactivation of the cullin 3 adapter protein-encoding leucine zipper-like transcription regulator 1 (LZTR1) gene led to enhanced mitogen-activated protein kinase (MAPK) pathway activity and reduced sensitivity to tyrosine kinase inhibitors. Knockdown of the Drosophila LZTR1 ortholog CG3711 resulted in a Ras-dependent gain-of-function phenotype. Endogenous human LZTR1 associates with the main RAS isoforms. Inactivation of LZTR1 led to decreased ubiquitination and enhanced plasma membrane localization of endogenous KRAS (V...
Source: ScienceNOW - December 6, 2018 Category: Science Authors: Bigenzahn, J. W., Collu, G. M., Kartnig, F., Pieraks, M., Vladimer, G. I., Heinz, L. X., Sedlyarov, V., Schischlik, F., Fauster, A., Rebsamen, M., Parapatics, K., Blomen, V. A., Müller, A. C., Winter, G. E., Kralovics, R., Brummelkamp, T. R., Mlod Tags: Cell Biology, Medicine, Diseases reports Source Type: news

New Phase 3 Study Findings Show IMBRUVICA ® (ibrutinib) Plus Rituximab Significantly Improved Survival Compared to Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Previously Untreated Patients Aged 70 or Younger with Chronic Lymphocytic Leukemia
(Source: Johnson and Johnson)
Source: Johnson and Johnson - December 4, 2018 Category: Pharmaceuticals Source Type: news

Ibrutinib plus rituximab superior to standard treatment for some patients with chronic leukemia
Chronic lymphocytic leukemia is one of the most common types of leukemia in adults typically occurring during or after middle age and rarely occurring in individuals under the age of 40. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - December 4, 2018 Category: American Health Source Type: news

New Venclexta/Venclyxto data demonstrate deep responses in two of the most common types of leukaemia
Roche today announced new data from the Venclexta ®/Venclyxto® (venetoclax) clinical development programme, including longer-term results from the phase III MURANO study in people with previously treated chronic lymphocytic leukaemia (CLL) and updated data from two phase Ib/II studies in people with previously untreated acute myeloid leukaemia (A ML) ineligible for intensive chemotherapy due to coexisting medical conditions. (Source: Roche Media News)
Source: Roche Media News - December 4, 2018 Category: Pharmaceuticals Source Type: news

New Venclexta/Venclyxto data demonstrate deep responses in two of the most common types of leukaemia
Roche today announced new data from the Venclexta ®/Venclyxto® (venetoclax) clinical development programme, including longer-term results from the phase III MURANO study in people with previously treated chronic lymphocytic leukaemia (CLL) and updated data from two phase Ib/II studies in people with previously untreated acute myeloid leukaemia (A ML) ineligible for intensive chemotherapy due to coexisting medical conditions. (Source: Roche Investor Update)
Source: Roche Investor Update - December 4, 2018 Category: Pharmaceuticals Source Type: news

Amgen Announces First-In-Human Data Evaluating Investigational Novel BiTE ® Immunotherapies AMG 420 And AMG 330 At ASH 2018
Phase 1 Results of Amgen's BiTE® Platform in Heavily Pre-Treated Patients With Multiple Myeloma and Acute Myeloid Leukemia FDA Grants Fast Track Designation for AMG 420 THOUSAND OAKS, Calif., Dec. 3, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the first clinical results from studies evaluating investigational novel bispecific T cell engager (BiTE®) immunotherapies AMG 420 and AMG 330. In two separate Phase 1 dose escalation studies, AMG 420, which targets B-cell maturation antigen (BCMA), and AMG 330, which targets CD33, provided early evidence of tolerability and anti-tumor activity in pat...
Source: Amgen News Release - December 4, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

New Combo Therapy Shows Promise in Leukemia
Leukemia cells show sensitivity to restriction of BCL2 and BTK with the combination of venetoclax and ibrutinib. (Source: CancerNetwork)
Source: CancerNetwork - December 4, 2018 Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news

Ibrutinib Alone for Older Patients With Untreated CLL Ibrutinib Alone for Older Patients With Untreated CLL
Ibrutinib alone and ibrutinib with rituximab were both superior to the bendamustine – rituximab combination for older patients with chronic lymphocytic leukemia (CLL).Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 3, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

IMBRUVICA ® (ibrutinib) Plus Obinutuzumab Showed Significant Improvement in Progression-Free Survival Compared to Chlorambucil Plus Obinutuzumab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
(Source: Johnson and Johnson)
Source: Johnson and Johnson - December 3, 2018 Category: Pharmaceuticals Source Type: news

ASH: Ibrutinib Tops Bendamustine & #43; Rituximab for CLL
MONDAY, Dec. 3, 2018 -- For older patients with untreated chronic lymphocytic leukemia (CLL), treatment with ibrutinib alone or in combination with rituximab is associated with improved progression-free survival versus bendamustine plus rituximab,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 3, 2018 Category: Pharmaceuticals Source Type: news

Droplet Digital PCR's ability to detect minimal residual disease underscored by researchers at 60th ASH Annual Meeting & Exposition
(CG Life) More than 30 abstracts presented at the 60th ASH Annual Meeting& Exposition in San Diego, December 1-4, featured research highlighting the ability of Bio-Rad's Droplet Digital PCR to provide high sensitivity and accuracy in quantifying minimal residual disease (MRD) -- those remaining cancer cells after therapy that are associated with relapse -- in blood diseases such as leukemia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 3, 2018 Category: Cancer & Oncology Source Type: news

Dana-Farber researchers report clinical trial results in treatment of leukemia & lymphoma
(Dana-Farber Cancer Institute) New results from clinical trials of immunotherapy and experimental targeted agents for patients with leukemia and lymphoma are being presented by Dana-Farber Cancer Institute researchers at the ASH Annual Meeting. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 2, 2018 Category: Cancer & Oncology Source Type: news

Leukemia Relapses May Arise From Specialized Cells
Targeting the transient group of cells could prevent recurrence of the disease. (Source: The Scientist)
Source: The Scientist - December 1, 2018 Category: Science Tags: The Literature Magazine Issue Source Type: news

Screening LSCs For AML Drug Resistance, Sensitivity
Researchers used high throughput drug screening on leukemic stem cells to determine drug resistance and sensitivity in acute myeloid leukemia patients. (Source: CancerNetwork)
Source: CancerNetwork - November 30, 2018 Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news

Allogeneic Transplantation in Elderly AML Patients
Allogeneic hematopoietic stem cell transplantation could improve outcomes of elderly patients with acute myeloid leukemia. (Source: CancerNetwork)
Source: CancerNetwork - November 30, 2018 Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news

St. Jude research into leukemia, sickle cell and other blood disorders presented at ASH
(St. Jude Children's Research Hospital) The 60th Annual Meeting of the American Society of Hematology will feature research from St. Jude Children's Research Hospital on topics ranging from the genomic basis and vulnerabilities of leukemia to an update on gene therapy for hemophilia B to advances in sickle cell disease and beta-thalassemia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 30, 2018 Category: Cancer & Oncology Source Type: news

Experts present new recommendations on 'overlapping' type of leukemia
(Wolters Kluwer Health) Chronic myelomonocytic leukemia (CMML) is a rare disease with overlapping features of two categories of bone marrow and blood cell disorders that poses challenges in clinical management. Joint recommendations on diagnosis and treatment of CMML from two European specialty societies were published today in HemaSphere, the official journal of the European Hematology Association (EHA). The journal is published in the Lippincott portfolio by Wolters Kluwer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 30, 2018 Category: International Medicine & Public Health Source Type: news

FDA Warns About Serious Adverse Effect of AML Drug Enasidenib FDA Warns About Serious Adverse Effect of AML Drug Enasidenib
A life-threatening adverse effect called differentiation syndrome is not being recognized in patients receiving the acute myeloid leukemia drug enasidenib, says the FDA.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 30, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA Warns About Dangerous Side Effect of AML Drug Enasidenib FDA Warns About Dangerous Side Effect of AML Drug Enasidenib
A life-threatening side effect called differentiation syndrome is not being recognized in patients receiving the acute myeloid leukemia drug enasidenib, says the FDA.News Alerts (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 29, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

For Chronic Leukemia Patients, the News Just Got Even Better
Several chronic lymphocytic leukemia (CLL) patients at the Wilmot Cancer Institute took part in two groundbreaking, nationwide phase 3 studies that are changing the way doctors treat the disease. The positive results are being reported this weekend at the 2018 American Society of Hematology (ASH) annual meeting — and will immediately impact CLL patients in the Rochester region and across the U.S., said Paul Barr, M.D., director of Wilmot’s Clinical Trials Office. (Source: University of Rochester Medical Center Press Releases)
Source: University of Rochester Medical Center Press Releases - November 29, 2018 Category: Universities & Medical Training Authors: University of Rochester Medical Center Source Type: news

FDA Approves Treatment for AML Patients With Gene Mutation
THURSDAY, Nov. 29, 2018 -- Xospata (gilteritinib) tablets were approved today by the U.S. Food and Drug Administration for treatment of relapsed or refractory acute myeloid leukemia (AML) in adults with an FLT3 mutation, the agency announced in a... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 29, 2018 Category: Pharmaceuticals Source Type: news

FDA warns that symptoms of a serious condition affecting the blood cells are not being recognized with the leukemia medicine Idhifa (enasidenib)
(Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - November 29, 2018 Category: Drugs & Pharmacology Source Type: news

Wendy Atkin obituary
Epidemiologist whose research led to a breakthrough in bowel cancer screening programmes worldwide“Breakthrough” is an overused word when applied to medical advances. But in the case of the2010 trial of a new screening test for bowel cancer led by Wendy Atkin, professor of gastrointestinal epidemiology atImperial College London, who has died of acute myeloid leukaemia aged 71, it is fully deserved. Its impact will be felt by millions. The trial was the first in the world to show that bowel cancer – the second biggest cancer killer in the UK – could be prevented with a simple, five-minute test.The ex...
Source: Guardian Unlimited Science - November 29, 2018 Category: Science Authors: Ara Darzi Tags: Cancer research Health Medical research Science Source Type: news

Inconspicuous protein key to deadly blood cancer
(Cold Spring Harbor Laboratory) Mixed lineage leukemia (MLL) is a very aggressive blood cancer, capable of causing the growth of cancerous cells in numerous ways. Now, researchers at CSHL have revealed that a remarkably common protein is behind the cancer's drivers. By taking it away, the disease collapses. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 29, 2018 Category: Cancer & Oncology Source Type: news

Venetoclax combination approved for elderly AML
(Dana-Farber Cancer Institute) Older patients with acute myeloid leukemia (AML) often aren't healthy enough to receive intensive chemotherapy, and gentler treatments aren't very effective in treating this aggressive blood cancer.But a new option -- a combination of a standard drug and the novel agent venetoclax -- has been granted accelerated approval by the Food and Drug Administration for such patients after a large, multicenter phase 1 clinical trial showed the combination had 'promising efficacy' and was well tolerated in older AML patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 29, 2018 Category: International Medicine & Public Health Source Type: news

FDA Approves Gilteritinib for FLT3+ Acute Myeloid Leukemia FDA Approves Gilteritinib for FLT3+ Acute Myeloid Leukemia
The FDA's approval is for the first drug targeting FLT3 mutations in AML.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 28, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

Single-Agent FLT3 Inhibitor Gets FDA Nod for Acute Leukemia
(MedPage Today) -- First monotherapy OK'd for relapsed or refractory patients with FLT3 mutation (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 28, 2018 Category: Hematology Source Type: news

FDA Approves Xospata (gilteritinib) for Acute Myeloid Leukemia (AML) with a FLT3 Mutation
November 28, 2018 -- The U.S. Food and Drug Administration today approved Xospata (gilteritinib) tablets for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 28, 2018 Category: Drugs & Pharmacology Source Type: news

FDA approves treatment for adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a certain genetic mutation
The FDA approved Xospata (gilteritinib) tablets for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test. (Source: Food and Drug Administration)
Source: Food and Drug Administration - November 28, 2018 Category: American Health Source Type: news

91 percent response rate for venetoclax against newly diagnosed AML in older adults
Clinical trial results published in the journal Nature Medicine show 91 percent response rate to the combination of venetoclax with azacitidine in older adults newly diagnosed with acute myeloid leukemia (AML). Of 33 patients given combination venetoclax and azacitidine, 20 experienced a complete response (aka complete remission) and eight experienced a complete response but with continued low blood counts. (Source: World Pharma News)
Source: World Pharma News - November 28, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Healthy blood stem cells have as many DNA mutations as leukemic cells
(Princess Máxima Center for Pediatric Oncology) Researchers from the Princess M á xima Center for Pediatric Oncology have shown that the number of mutations in healthy and leukemic blood stem cells does not differ. Rather the location of the mutations in the DNA is relevant. Using the mutation patterns in the hematopoietic stem and progenitor cells (HSPCs) the team was able to trace the developmental lineage tree of the cells. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 28, 2018 Category: International Medicine & Public Health Source Type: news

FDA approves new targeted drug for leukemia tested at University of Pennsylvania
(University of Pennsylvania School of Medicine) The US Food and Drug Administration (FDA) has approved the first ever inhibitor drug specifically approved for treating patients with relapsed or refractory acute myeloid leukemia (AML) with a mutation in the Fms-like tyrosine kinase 3 (FLT3) gene. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 28, 2018 Category: Cancer & Oncology Source Type: news

91 percent response rate for venetoclax against newly diagnosed AML in older adults
(University of Colorado Anschutz Medical Campus) Clinical trial results published in the journal Nature Medicine and being presented this weekend at the American Society for Hematology Annual Meeting show 91 percent response rate to the combination of venetoclax with azacitidine in older adults newly diagnosed with acute myeloid leukemia (AML). Of 33 patients given combination venetoclax and azacitidine, 20 experienced a complete response (aka complete remission) and eight experienced a complete response but with continued low blood counts. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 28, 2018 Category: Cancer & Oncology Source Type: news

New stem-cell therapy to improve fight against leukemia
(University of Zurich) Stem-cell transplantation is an effective form of therapy to fight leukemia. In many cases, however, the transferred immune cells of the donor also attack the recipients' healthy tissue - often with fatal consequences. Researchers at the University of Zurich have now identified a molecule that plays a key role in this process. Blocking this molecule could significantly improve the outcome of patients receiving stem-cell transplants. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 28, 2018 Category: Cancer & Oncology Source Type: news

FDA Approves New Treatment for Acute Myeloid Leukemia
Randomized clinical trial showed significant improvement in overall survival with Daurismo (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - November 27, 2018 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Geriatrics, Institutional, Source Type: news

Pfizer nabs fourth oncology approval in two months
The FDA has approved Pfizer ’s new drug, Daurismo, for patients with acute myeloid leukemia. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - November 26, 2018 Category: Pharmaceuticals Source Type: news

FDA Approves New Treatment for Acute Myeloid Leukemia
MONDAY, Nov. 26, 2018 -- The U.S. Food and Drug Administration recently announced the approval of Daurismo (glasdegib) tablets for use in combination with a low dose of the chemotherapy cytarabine to treat newly diagnosed acute myeloid leukemia... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 26, 2018 Category: Pharmaceuticals Source Type: news

Pregnant mother-of-3 desperately searches for bone marrow donor after 30 million failed matches
Susie Rabaca, 36, is a mother of three, pregnant with twins and dying of leukemia. She needs a bone marrow transplant, finding a match is difficult simply because Rabaca is mixed-race. a (Source: the Mail online | Health)
Source: the Mail online | Health - November 23, 2018 Category: Consumer Health News Source Type: news

What's Hot at This Year's ASH Meeting? What's Hot at This Year's ASH Meeting?
Big results from big trials in leukemia and lymphoma will be presented and are'almost certainly going to be practice changing,'says American Society of Hematology (ASH) Secretary Robert Brodsky, MD.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 23, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Add new lung cancer treatment to Cancer Drugs Fund, says NICE
3000+ patients set to benefit from provisional thumbs up for immunotherapy drug Keytruda Related items fromOnMedica Is crowdfunding for cancer patients paying for ‘quackery’? Call for NHS England to ‘think again’ on limiting treatment Put case for adding leukaemia drug to Cancer Drugs Fund, NICE tells company Cancer patients using complementary meds die sooner NICE calls for safer use of controlled drugs (Source: OnMedica Latest News)
Source: OnMedica Latest News - November 23, 2018 Category: UK Health Source Type: news

FDA approves new treatment for patients with acute myeloid leukemia
The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are 75 years of age or older or who have other chronic health conditions or diseases (comorbidities) that may preclude the use of intensive chemotherapy. (Source: World Pharma News)
Source: World Pharma News - November 22, 2018 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Leukemia epigenetics in focus
(Wiley) Some severe forms of leukemia develop because proteins on the epigenetic level lose their regulative function. Now, in a broad international collaboration, UK researchers have identified molecules that can effectively inhibit the dysregulated proteins. In the journal Angewandte Chemie, researchers report the discovery, design, and testing of potential drugs on the cellular level. The findings set the stage for new biological experiments and cancer treatment approaches in the future. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 22, 2018 Category: Cancer & Oncology Source Type: news

Roche announces FDA grants Venclexta accelerated approval for people with newly-diagnosed acute myeloid leukaemia or those who are ineligible for intensive induction chemotherapy
Roche today announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Venclexta ® (venetoclax), in combination with a hypomethylating agent (azacitidine or decitabine), or low dose cytarabine (LDAC), for the treatment of people with newly-diagnosed acute myeloid leukaemia (AML), who are age 75 years or older, or for those ineligible for intensive induction chemotherapy due to coexisting medical conditions. (Source: Roche Media News)
Source: Roche Media News - November 21, 2018 Category: Pharmaceuticals Source Type: news

Roche announces FDA grants Venclexta accelerated approval for people with newly-diagnosed acute myeloid leukaemia or those who are ineligible for intensive induction chemotherapy
Roche today announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Venclexta ® (venetoclax), in combination with a hypomethylating agent (azacitidine or decitabine), or low dose cytarabine (LDAC), for the treatment of people with newly-diagnosed acute myeloid leukaemia (AML), who are age 75 years or older, or for those ineligible for intensive induction chemotherapy due to coexisting medical conditions. (Source: Roche Investor Update)
Source: Roche Investor Update - November 21, 2018 Category: Pharmaceuticals Source Type: news